We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves Vraylar to Treat Bipolar Disorder, Schizophrenia
FDA Approves Vraylar to Treat Bipolar Disorder, Schizophrenia
Allergan and partner Gedeon Richter received FDA approval Thursday for antipsychotic Vraylar to treat schizophrenia and manic or mixed episodes associated with bipolar I disorder in adults.